Study	Reason for exclusion
Gobbur 2011	Randomised controlled trial, but sequence generation and allocation concealment were not described. Intervention group (N = 50) ‐ 1 g of TA IV 20 minutes prior to CS. Control group (N = 50) ‐ received no intervention. Outcomes ‐ blood loss from placental delivery until the end of CS and until 2 hours postpartum. This study was published only in abstract form in 2011. The information in the abstract is not sufficient for adequate appraisal.
Gohel 2007	This was a quasi‐randomised trial (randomisation by the rule of odds and even). This study reported decreased blood loss in 50 women who received 1 g of TA IV 20 minutes prior to CS, in comparison to 50 women who did not receive the drug. No side effects were reported in either group.
Halder 2013	Although the title of this report says "randomised case‐controlled study" it is not clear from the report whether the study was indeed randomised. It states that participants were divided in 2 groups, but there is not any description of sequence generation or allocation concealment. The blood loss is measured from placental delivery to 2 days postpartum and no difference between the groups was found.
Sekhavat 2009	This was a quasi‐randomised trial (randomisation by the rule of odds and even). This study reported decreased blood loss from the end of CS until 2 hours postpartum in 45 women who received 1 g of TA IV 10 minutes prior to CS, in comparison to 45 women who did not receive the drug. Haemoglobin level was significantly greater in TA group. No side effects were reported in either group.
Tarabrin 2012	This trial in published only in 2 abstracts. Information provided in abstracts is not sufficient for adequate appraisal.

CS: caesarean section
 IV: intravenously
 PPH: postpartum haemorrhage
 TA: tranexamic acid